Circadian variation of Valproic acid pharmacokinetics in mice

被引:25
作者
Ben-Cherif, Wafa [1 ]
Dridi, Ichrak [1 ]
Aouam, Karim [1 ]
Ben-Attia, Mossadok [2 ]
Reinberg, Alain [3 ]
Boughattas, Naceur A. [1 ]
机构
[1] Univ Monastir, Fac Med, Pharmacol Lab, Monastir 5019, Tunisia
[2] Univ Carthage, Fac Sci Bizerte, Lab Biomonitoring Environm LR01 ES14, Zarzouna 7021, Bizerte, Tunisia
[3] Fdn Adolphe De Rothschild, Unit Chronobiol, Paris, France
关键词
Valproic acid; Pharmacokinetics; Circadian rhythm; Mice; Cosinor method; DIURNAL-VARIATION; SODIUM VALPROATE; DRUG DISPOSITION; PROTEIN-BINDING; CHRONOPHARMACOKINETICS; RHYTHMS; CLOCK; VARIABILITY; METABOLISM; GENES;
D O I
10.1016/j.ejps.2013.05.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Valproic acid (VPA) is currently one of the most commonly used antiepileptic drugs. This study aims to investigate whether VPA pharmacokinetics varied according to circadian dosing-time. A single dose of VPA (350 mg kg(-1)) was administered by intraperitonally (i.p.) route to a total of 132 mice synchronized for 3 weeks to 12 h light (rest span) and 12 h dark (activity span). Four different circadian times (I, 7, 13 and 19 HALO) of drug injection were used (33 mice/circadian time). At each circadian time, blood samples were withdrawn at (0 h) and at 0.083, 0.166, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2 and 3 h after VPA injection. Plasma VPA concentrations were determined by an EMIT method. There were no significant differences in T-max. of VPA whatever the circadian-time of injections (T-max = 0.166 h). However, there were relevant differences in C-max between the four circadian groups (p < 0.005), it varied between 386 30.86 mg L-1 in mice treated at 7 HALO and 824 +/- 39.85 mg L-1 in mice treated at 19 HALO. The AUC(0-infinity) was significantly two times higher when VPA was administered at 19 HALO as compared to the injection at 7 HALO. Drug dosing at 7 HALO resulted in highest C1(T) value: 0.405 +/- 0.006 L h(-1) kg(-1), whereas Cl-T was significantly slower when VPA was administered at 19 HALO (0.157 +/- 0.009 L h(-1) kg(-1)) (p < 0.0001). The AUC(0-infinity) a was significantly 2-fold higher when VPA was administered at 19 HALO (2216.65 +/- 138.91 mg h(-1) L-1) as compared to the injection at 7 HALO (864.09 +/- 16.82 mg h(-1) L-1) (p < 0.0001). Cosinor analysis showed circadian rhythm in different pharmacokinetic parameters. C-max and AUC(0-infinity) have a significant circadian rhythm with an acrophase located at 20.16 HALO +/- 0.16 h (the middle of the active span) (p < 0.001), whereas CIT and Vd showed a significant circadian rhythm with an acrophase located respectively at 7.86 HALO +/- 0.57 h and 6.13 HALO +/- 0.07 h (the middle of the rest span) (p < 0.001). The large circadian variation of VPA pharmacokinetic processes might be involved in the mechanisms of circadian rhythm in murine toxicity since the optimal tolerance corresponded to the time which induces lowest C-max and AUC values. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:468 / 473
页数:6
相关论文
共 45 条
[1]  
[Anonymous], ADV DRUG RES
[2]   DIURNAL-VARIATION IN VALPROIC ACID CLEARANCE [J].
BAUER, LA ;
DAVIS, R ;
WILENSKY, A ;
RAISYS, V ;
LEVY, RH .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 35 (04) :505-509
[3]   VALPROIC ACID CLEARANCE - UNBOUND FRACTION AND DIURNAL-VARIATION IN YOUNG AND ELDERLY ADULTS [J].
BAUER, LA ;
DAVIS, R ;
WILENSKY, A ;
RAISYS, V ;
LEVY, RH .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 37 (06) :697-700
[4]  
Ben-Cherif Wafa, 2012, J Circadian Rhythms, V10, P3, DOI 10.1186/1740-3391-10-3
[5]   Effect of valproate on the metabolism of the central nervous system [J].
Bolanos, JP ;
Medina, JM .
LIFE SCIENCES, 1997, 60 (22) :1933-1942
[6]   RECENT ADVANCES IN CHRONOPHARMACOKINETICS - METHODOLOGICAL PROBLEMS [J].
BRUGUEROLLE, B ;
LEMMER, B .
LIFE SCIENCES, 1993, 52 (23) :1809-1824
[7]   Chronopharmacokinetics - Current status [J].
Bruguerolle, B .
CLINICAL PHARMACOKINETICS, 1998, 35 (02) :83-94
[8]  
Bruguerolle B, 2009, ENCEPHALE, V35, pS58, DOI 10.1016/S0013-7006(09)75535-6
[9]  
Bruguerolle B., 2008, ANNALES PHARMACEUTIQUES FRANCAISES, V66, P185, DOI 10.1016/j.pharma.2008.05.005
[10]  
Gandhi A., 2012, CURR DRUG M IN PRESS